Darryl Leong, PHRI Scientist, is among six recipients of Canadian Cancer Society/CIHR Cancer Survivorship Team Grants, less than a quarter of all full proposals received in the competition. His winning proposal – on the topic of cardiovascular and other comorbidities in patients with cancer (C3) – will receive a total of $2,384,321 in funding between now and 2024.
“This funding will allow us to recruit and follow more than 4000 participants with prostate or breast cancer in Canada and internationally in our clinical trials,” says Dr. Leong.
The PHRI/McMaster University team grant is based on the proposal of two research projects (Darryl Leong is a PI on both) that will address two key cardiovascular problems:
- Men with prostate cancer [RADICAL PC-Observational; RADICAL PC-Interventional.]
- Individuals with breast cancer who develop cardiotoxicity from trastuzumab, a life-prolonging therapy for many breast cancer survivors. [SCHOLAR-2].
“C3 is of growing importance as it has been shown that cancer is the leading cause of death now in many countries,: notes Dr. Leong, a co-Principal Investigator in the 2019 analysis of PURE data that showed the rise of cancers relative to other causes of death and disease in globally changing patterns (published in The Lancet).